According to the 2025 ESMO TAT Honorary Awardee, Prof. Philippe Bedard, new technologies have the potential to increase the wealth of information generated from trials and registries
With its new peer-reviewed journal dedicated to rare tumours, ESMO supports knowledge and data sharing among the stakeholders in the field
Recent research suggests a substantial reduction in greenhouse gas emissions with de-escalation per cancer patient
The updated Antineoplastic Medicine Survey (ANMS) dataset shows that essential therapies remain out of reach for patients in most low and lower middle-income countries despite international efforts
Effectiveness, applicability and accessibility measure the value of novel technologies and therapies in oncology
The latest tumour types covered in the ESMO PAGAs are biliary tract cancers, oncogene-addicted metastatic non-small cell lung cancer and epithelial ovarian cancer
Long-term multisectoral preventive actions that take into account local requirements are needed
The deployment of artificial intelligence could lead to substantial advances in cancer care, but collaborative efforts are needed to increase trust among end users
Some initiatives show that collection and distribution of unused medicines can help tackle drug waste, with a potential impact on emissions associated to oncology therapies
Together with an off-trial use and off-track access to oncology therapies, a consolidated trend is reported in clinical practice despite the uncertainties on efficacy and safety
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.